Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية رضا جردانة - reda jardaneh drug store - cilastatin 500 mg/vial, imipenem anhydrous 500 mg/vial - 500 mg/vial, 500 mg/vial

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع البتراء للمواد الطبية - petra drug store - vancomycin 1 g/vial - 1 g/vial

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

arabian ethicals co. united arab emirates - 5's (5 single use glass vials) - injection - 40mg/vial - gastrointestinal system-ulcer-healing

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع الأدوية الأردني - the jordan drugstore co - desferrioxamine methane sulphonate 0.5 gm/vial - 0.5 gm/vial

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - pantoprazole sodium, quantity: 42.29 mg (equivalent: pantoprazole, qty 40 mg) - injection, powder for - excipient ingredients: sodium hydroxide; nitrogen - for short-term use where oral therapy is not appropriate for the following conditions: 1. symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion, e.g. duodenal ulcer, gastric ulcer, reflux oesophagitis, gastrointestinal lesions refractory to h2 blockers, zollinger-ellison syndrome. 2. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. note: patients whose gastric or duodenal ulceration is not associated with ingestion of nonsteroidal anti-inflammatory drugs require treatment with anti-microbial agents in addition to anti-secretory medicines, whether on first presentation or recurrence.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - pantoprazole sodium, quantity: 42.29 mg (equivalent: pantoprazole, qty 40 mg) - injection, powder for - excipient ingredients: sodium hydroxide; nitrogen - for short-term use where oral therapy is not appropriate for the following conditions: 1. symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion, e.g. duodenal ulcer, gastric ulcer, reflux oesophagitis, gastrointestinal lesions refractory to h2 blockers, zollinger-ellison syndrome. 2. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. note: patients whose gastric or duodenal ulceration is not associated with ingestion of nonsteroidal anti-inflammatory drugs require treatment with anti-microbial agents in addition to anti-secretory medicines, whether on first presentation or recurrence.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - pantoprazole sodium, quantity: 42.29 mg (equivalent: pantoprazole, qty 40 mg) - injection, powder for - excipient ingredients: sodium hydroxide; nitrogen - for short-term use where oral therapy is not appropriate for the following conditions: 1. symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion, e.g. duodenal ulcer, gastric ulcer, reflux oesophagitis, gastrointestinal lesions refractory to h2 blockers, zollinger-ellison syndrome. 2. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. note: patients whose gastric or duodenal ulceration is not associated with ingestion of nonsteroidal anti-inflammatory drugs require treatment with anti-microbial agents in addition to anti-secretory medicines, whether on first presentation or recurrence.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - pantoprazole sodium, quantity: 42.29 mg (equivalent: pantoprazole, qty 40 mg) - injection, powder for - excipient ingredients: sodium hydroxide; nitrogen - for short-term use where oral therapy is not appropriate for the following conditions: 1. symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion, e.g. duodenal ulcer, gastric ulcer, reflux oesophagitis, gastrointestinal lesions refractory to h2 blockers, zollinger-ellison syndrome. 2. maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis. note: patients whose gastric or duodenal ulceration is not associated with ingestion of nonsteroidal anti-inflammatory drugs require treatment with anti-microbial agents in addition to anti-secretory medicines, whether on first presentation or recurrence.

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

arabian ethicals co. united arab emirates - 10 glass vials - injection - 500mg/vial - infections-antibacterial

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية الفياصل - al-faiasel drug store - cefotaxime as sodium 0.5 gm/vial - as sodium 0.5 gm/vial